

We are thrilled to announce that Dr. Etienne Mahe has been appointed as the new Co-Director of the Cancer Translational Research Core, effective immediately.

Dr. Mahe is a hematopathologist and molecular pathologist. He is a Clinical Associate Professor in the Department of Pathology & Laboratory Medicine, with cross appointment in in the Department of Medicine at the Cumming School of Medicine. Dr. Mahe's primary research interests relate to the molecular genetics of T and B-cell clonality, and the molecular genetics of hematolymphoid malignancies. Dr. Mahe actively contributes to ongoing learning as course director for MDSC_BIOL 515 Cellular Mechanisms of Disease in the Bachelor of Health Sciences program.



As Co-Director of the Cancer Translational Research Core at the Arthur Child Comprehensive Cancer Centre (AC-TRC), Dr. Mahe will collaborate with local and provincial pathology leaders to align the AC-TRC's activities with broader healthcare objectives. He will also enhance the development and support of clinical-grade testing within the core where opportunities for advancement exists. Additionally, he will enable translation of research into clinical practices that improve patient outcomes.

Dr. Mahe will work alongside the core's Scientific Director, Dr. Paola Neri, to steer the strategic direction of the AC-TRC, ensuring it remains at the forefront of cancer translational research. We are incredibly excited to welcome Dr. Mahe into this role. His leadership is poised to invigorate our mission to transform scientific discoveries into treatments that benefit cancer patients.

The Cancer Translational Research Core (TRC) at the Arthur Child Comprehensive Cancer Centre is a facility dedicated to supporting the development of more precise diagnostics and more effective treatments for cancer patients through facilitating translational cancer research. The Arthur Child-TRC has been developed in partnership with the Cumming School of Medicine and Alberta Health Services, and involving the Charbonneau Cancer Institute, the Departments of Oncology and Pathology & Laboratory Medicine, and Alberta Precision Laboratories.